Although we presented interesting and potentially important data on the loss of MLH1/PMS2 expression in different stages of BE, due to small number of patients and retrospective analysis, we cannot conclude that MSI can be used as a biomarker to stratify the risk of EAC development. The gene discussed is MLH1; the disease is Barrett esophagus.